SG11202111606TA - Bicyclic peptide ligands specific for ox40 - Google Patents
Bicyclic peptide ligands specific for ox40Info
- Publication number
- SG11202111606TA SG11202111606TA SG11202111606TA SG11202111606TA SG11202111606TA SG 11202111606T A SG11202111606T A SG 11202111606TA SG 11202111606T A SG11202111606T A SG 11202111606TA SG 11202111606T A SG11202111606T A SG 11202111606TA SG 11202111606T A SG11202111606T A SG 11202111606TA
- Authority
- SG
- Singapore
- Prior art keywords
- peptide ligands
- ligands specific
- bicyclic peptide
- bicyclic
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962845473P | 2019-05-09 | 2019-05-09 | |
PCT/GB2020/051144 WO2020225577A1 (en) | 2019-05-09 | 2020-05-11 | Bicyclic peptide ligands specific for ox40 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202111606TA true SG11202111606TA (en) | 2021-11-29 |
Family
ID=70847426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202111606TA SG11202111606TA (en) | 2019-05-09 | 2020-05-11 | Bicyclic peptide ligands specific for ox40 |
Country Status (12)
Country | Link |
---|---|
US (1) | US11613560B2 (en) |
EP (1) | EP3965827A1 (en) |
JP (1) | JP2022532134A (en) |
KR (1) | KR20220007098A (en) |
CN (1) | CN113811541A (en) |
AU (1) | AU2020269506A1 (en) |
BR (1) | BR112021022315A2 (en) |
CA (1) | CA3137095A1 (en) |
IL (1) | IL287881A (en) |
MX (1) | MX2021013669A (en) |
SG (1) | SG11202111606TA (en) |
WO (1) | WO2020225577A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI825046B (en) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Bicyclic peptide ligands specific for epha2 |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
KR20220007098A (en) | 2019-05-09 | 2022-01-18 | 바이사이클티엑스 리미티드 | Bicyclic peptide ligand specific for OX40 |
TW202110485A (en) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | Heterotandem bicyclic peptide complex |
US11332500B2 (en) | 2019-10-03 | 2022-05-17 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
EP4274844A1 (en) * | 2021-01-08 | 2023-11-15 | BicycleTx Limited | Heterotandem bicyclic peptide complexes |
CN118055772A (en) * | 2021-09-29 | 2024-05-17 | 星联肽(珠海)生物科技有限公司 | Tricyclic polypeptide coupling medicine and application thereof |
CN114933638A (en) * | 2022-05-12 | 2022-08-23 | 厦门大学 | Polycyclopeptide ligand framework specifically targeting CD28 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
EP2653544A1 (en) | 2008-02-05 | 2013-10-23 | Bicycle Therapeutics Limited | Methods and compositions |
GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
WO2012057624A1 (en) | 2010-10-25 | 2012-05-03 | Pepscan Systems B.V. | Novel bicyclic peptide mimetics |
WO2014190257A2 (en) | 2013-05-23 | 2014-11-27 | Ohio State Innovation Foundation | Chemical synthesis and screening of bicyclic peptide libraries |
HUE045872T2 (en) | 2014-05-21 | 2020-01-28 | Entrada Therapeutics Inc | Cell penetrating peptides and methods of making and using thereof |
AU2015340300B2 (en) | 2014-10-29 | 2019-12-05 | Bicyclerd Limited | Bicyclic peptide ligands specific for MT1-MMP |
MA45328A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
WO2017182672A1 (en) | 2016-04-22 | 2017-10-26 | Alligator Bioscience Ab | Novel bispecific polypeptides against cd137 |
GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
US11730819B2 (en) | 2016-12-23 | 2023-08-22 | Bicycletx Limited | Peptide derivatives having novel linkage structures |
US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
EP3661948B1 (en) | 2017-08-04 | 2022-06-01 | BicycleTx Limited | Bicyclic peptide ligands specific for cd137 |
TWI825046B (en) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Bicyclic peptide ligands specific for epha2 |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
BR112020014576A2 (en) | 2018-02-23 | 2020-12-08 | Bicycletx Limited | MULTIMERIC BICYCLIC PEPTIDE BINDERS |
US11453703B2 (en) | 2018-04-04 | 2022-09-27 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
US10919937B2 (en) | 2018-10-23 | 2021-02-16 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
US20220306689A9 (en) | 2018-12-21 | 2022-09-29 | Bicycletx Limited | Bicyclic peptide ligands specific for pd-l1 |
SG11202110828UA (en) | 2019-04-02 | 2021-10-28 | Bicycletx Ltd | Bicycle toxin conjugates and uses thereof |
KR20220007098A (en) | 2019-05-09 | 2022-01-18 | 바이사이클티엑스 리미티드 | Bicyclic peptide ligand specific for OX40 |
TW202110485A (en) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | Heterotandem bicyclic peptide complex |
US11332500B2 (en) | 2019-10-03 | 2022-05-17 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
IL293200A (en) | 2019-11-27 | 2022-07-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for epha2 and uses thereof |
CN115698720A (en) | 2020-06-12 | 2023-02-03 | 拜斯科技术开发有限公司 | Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocyte receptor A2 (EPHA 2) |
-
2020
- 2020-05-11 KR KR1020217039675A patent/KR20220007098A/en unknown
- 2020-05-11 WO PCT/GB2020/051144 patent/WO2020225577A1/en unknown
- 2020-05-11 SG SG11202111606TA patent/SG11202111606TA/en unknown
- 2020-05-11 JP JP2021566259A patent/JP2022532134A/en active Pending
- 2020-05-11 CN CN202080033959.9A patent/CN113811541A/en active Pending
- 2020-05-11 AU AU2020269506A patent/AU2020269506A1/en not_active Abandoned
- 2020-05-11 CA CA3137095A patent/CA3137095A1/en active Pending
- 2020-05-11 EP EP20728128.8A patent/EP3965827A1/en active Pending
- 2020-05-11 BR BR112021022315A patent/BR112021022315A2/en unknown
- 2020-05-11 MX MX2021013669A patent/MX2021013669A/en unknown
- 2020-05-11 US US16/872,097 patent/US11613560B2/en active Active
-
2021
- 2021-11-07 IL IL287881A patent/IL287881A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL287881A (en) | 2022-01-01 |
CN113811541A (en) | 2021-12-17 |
AU2020269506A1 (en) | 2022-01-06 |
WO2020225577A1 (en) | 2020-11-12 |
US20200354406A1 (en) | 2020-11-12 |
MX2021013669A (en) | 2021-12-10 |
BR112021022315A2 (en) | 2021-12-28 |
US11613560B2 (en) | 2023-03-28 |
EP3965827A1 (en) | 2022-03-16 |
CA3137095A1 (en) | 2020-11-12 |
KR20220007098A (en) | 2022-01-18 |
JP2022532134A (en) | 2022-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202100442B (en) | Bicyclic peptide ligands specific for nectin-4 | |
IL287881A (en) | Bicyclic peptide ligands specific for ox40 | |
IL283873A (en) | Bicyclic peptide ligands specific for mt1-mmp | |
GB201820316D0 (en) | Bicyclic peptide ligands specific for IL-17 | |
GB201900526D0 (en) | Bicyclic peptide ligands specific for caix | |
IL283874A (en) | Bicyclic peptide ligands specific for mt1-mmp | |
GB201820325D0 (en) | Bicyclic peptide ligands specific for psma | |
GB201820320D0 (en) | Bicyclic peptide ligands specific for FAPalpha | |
GB201820295D0 (en) | Bicyclic peptide ligands specific for MT1-MMP | |
GB201900525D0 (en) | Bicyclic peptide ligands specific for caix | |
GB201918495D0 (en) | Bicyclic peptide ligands specific for il-46 | |
GB201904632D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
GB201818499D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
GB201815684D0 (en) | Bicyclic peptide ligands specific for nectin-4 | |
GB201820322D0 (en) | Bicyclic peptide ligands specific for TGFbeta | |
GB201918559D0 (en) | Bicyclic peptide ligands specific for IL-17 | |
GB201918557D0 (en) | Bicyclic peptide ligands specific for IL-17 | |
GB201918558D0 (en) | Bicyclic peptide ligands specific for IL-17 | |
GB201820318D0 (en) | Bicyclic peptide ligands specific for cathepsin G | |
GB201820286D0 (en) | Bicyclic peptide ligands specific for mt1-mmp | |
GB201820310D0 (en) | Bicyclic peptide ligands specific for Hsp90 | |
GB201918489D0 (en) | Bicyclic peptide ligands specific for hsp90 | |
GB201820312D0 (en) | Bicyclic peptide ligands specific for IL-6 | |
GB201820321D0 (en) | Bicyclic peptide ligands specific for MMP9 | |
GB201820956D0 (en) | Bicyclic peptide ligands specific for pd-l1 |